中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

16 records (took 0.028 seconds)

    IMIDAZO[L,2-α]PYRIDINE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO
    1.
    发明申请
    IMIDAZO[L,2-α]PYRIDINE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO 审中-公开
    作为5-HT2A血清素受体调节剂的咪唑并[l，2-α]吡啶衍生物，用于治疗与其相关的病症

    公开(公告)号：WO2009023253A2

    公开(公告)日：2009-02-19

    申请号：PCT/US2008/009740

    申请日：2008-08-14

    Applicant: ARENA PHARMACEUTICALS INC. ,  XIONG, Yifeng ,  FEICHTINGER, Konrad ,  REN, Albert, S. ,  ULMANN, Brett

    Inventor： XIONG, Yifeng ,  FEICHTINGER, Konrad ,  REN, Albert, S. ,  ULMANN, Brett

    IPC: C07D471/04 ,  A61K31/437 ,  A61P25/20

    CPC classification number: A61K31/496 ,  A61K9/0019 ,  A61K9/0053 ,  A61K31/5377 ,  C07D471/04

    Abstract: rmidazo[l,2-α]pyridine derivatives of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the 5-HT 2A serotonin receptor. Compounds and pharmaceutical compositions thereof are directed to methods useful in the treatment of insomnia, dyssomnia, parasomnia and related sleep disorders, platelet aggregation, coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, atrial fibrillation, thrombosis, asthma or symptoms thereof, agitation or symptoms thereof, behavioral disorders, drug induced psychosis, excitative psychosis, Gilles de Ia Tourette's syndrome, manic disorder, organic or NOS psychosis, psychotic disorders, psychosis, acute schizophrenia, chronic schizophrenia, NOS schizophrenia and related disorders, diabetic- related disorders, progressive multifocal leukoencephalopathy and the like. The present invention also relates to methods for the treatment of 5-HT 2A serotonin receptor mediated disorders in combination with other pharmaceutical agents administered separately or together.

    Abstract translation: 式（Ia）的咪唑并[1,2-a]吡啶衍生物及其调节5-HT 2A受体5-羟色胺受体活性的药物组合物。 其化合物和药物组合物涉及用于治疗失眠，睡眠障碍，睡眠障碍和相关睡眠障碍，血小板聚集，冠状动脉疾病，心肌梗塞，短暂性脑缺血发作，心绞痛，中风，心房纤颤，血栓形成，哮喘或症状的方法 激动或其症状，行为障碍，药物诱发的精神病，兴奋性精神病，吉勒斯德拉图雷特综合征，躁狂症，有机或NOS精神病，精神病，精神病，急性精神分裂症，慢性精神分裂症，NOS精神分裂症和相关障碍， 相关疾病，进行性多灶性白质脑病等。 本发明还涉及与分开或一起施用的其它药剂联合治疗5-HT 2A受体5-羟色胺受体介导的病症的方法。

    INDAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO
    2.
    发明申请
    INDAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO 审中-公开
    吲唑衍生物作为5-HT2A血清素受体调节剂，用于治疗与其相关的疾病

    公开(公告)号：WO2008054748A3

    公开(公告)日：2008-08-07

    申请号：PCT/US2007022921

    申请日：2007-10-30

    Applicant: ARENA PHARM INC ,  FEICHTINGER KONRAD ,  XIONG YIFENG ,  CHOI JIN SUN KAROLINE ,  SMITH BRIAN M ,  STRAH-PLEYNET SONJA ,  TEEGARDEN BRADLEY

    Inventor： XIONG YIFENG ,  CHOI JIN SUN KAROLINE ,  SMITH BRIAN M ,  STRAH-PLEYNET SONJA ,  TEEGARDEN BRADLEY

    IPC: C07D231/56 ,  A61K31/496 ,  A61P7/00 ,  A61P11/00 ,  A61P25/18 ,  C07D403/06

    CPC classification number: C07D231/56 ,  C07D403/06

    Abstract: Indazole derivatives of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the serotonin 5HT 2A receptor. Formula (Ia) Compounds and pharmaceutical compositions thereof are directed to methods useful in the treatment of insomnia and related sleep disorders, platelet aggregation, coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, atrial fibrillation, reducing the risk of blood clot formation, asthma or symptoms thereof, agitation or symptoms thereof, behavioral disorders, drug induced psychosis, excitative psychosis, Gilles de Ia Tourette's syndrome, manic disorder, organic or NOS psychosis, psychotic disorders, psychosis, acute schizophrenia, chronic schizophrenia, NOS schizophrenia and related disorders, diabetic-related disorders, progressive multifocal leukoencephalopathy and the like. The present invention also relates to the methods for the treatment of 5-HT2A serotonin receptor mediated disorders in combination with other pharmaceutical agents administered separately or together.

    Abstract translation: 式（Ia）的吲唑衍生物及其调节血清素5HT2A受体活性的药物组合物。 式（Ia）化合物及其药物组合物涉及用于治疗失眠和相关睡眠障碍，血小板聚集，冠状动脉疾病，心肌梗塞，短暂性脑缺血发作，心绞痛，中风，心房纤颤，降低血液风险的方法 激动或其症状，行为障碍，药物诱导的精神病，兴奋性精神病，吉尔斯德拉图雷特综合征，躁狂症，有机或NOS精神病，精神病，精神病，急性精神分裂症，慢性精神分裂症，NOS精神分裂症 和相关病症，糖尿病相关病症，进行性多灶性白质脑病等。 本发明还涉及与单独或一起施用的其他药剂联合治疗5-HT 2A血清素受体介导的病症的方法。

    INDAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO
    6.
    发明申请
    INDAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO 审中-公开
    作为用于治疗相关疾病的5-HT2A丝氨酸受体有用的调节剂的吲哚衍生物

    公开(公告)号：WO2008054748A2

    公开(公告)日：2008-05-08

    申请号：PCT/US2007/022921

    申请日：2007-10-30

    Applicant: ARENA PHARMACEUTICALS, INC. ,  FEICHTINGER, Konrad ,  XIONG, Yifeng ,  CHOI, Jin Sun, Karoline ,  SMITH, Brian, M. ,  STRAH-PLEYNET, Sonja ,  TEEGARDEN, Bradley

    Inventor： XIONG, Yifeng ,  CHOI, Jin Sun, Karoline ,  SMITH, Brian, M. ,  STRAH-PLEYNET, Sonja ,  TEEGARDEN, Bradley

    CPC classification number: C07D231/56 ,  C07D403/06

    Abstract: Indazole derivatives of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the serotonin 5HT 2A receptor. Formula (Ia) Compounds and pharmaceutical compositions thereof are directed to methods useful in the treatment of insomnia and related sleep disorders, platelet aggregation, coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, atrial fibrillation, reducing the risk of blood clot formation, asthma or symptoms thereof, agitation or symptoms thereof, behavioral disorders, drug induced psychosis, excitative psychosis, Gilles de Ia Tourette's syndrome, manic disorder, organic or NOS psychosis, psychotic disorders, psychosis, acute schizophrenia, chronic schizophrenia, NOS schizophrenia and related disorders, diabetic-related disorders, progressive multifocal leukoencephalopathy and the like. The present invention also relates to the methods for the treatment of 5-HT2A serotonin receptor mediated disorders in combination with other pharmaceutical agents administered separately or together.

    Abstract translation: 式（Ia）的吲唑衍生物及其药物组合物，其调节5-羟色胺5HT 2A受体的活性。 式（Ia）化合物及其药物组合物涉及可用于治疗失眠和相关睡眠障碍，血小板聚集，冠状动脉疾病，心肌梗死，短暂性脑缺血发作，心绞痛，中风，心房颤动，降低血液风险的方法 凝块形成，哮喘或其症状，激动或其症状，行为障碍，药物诱导的精神病，兴奋性精神病，Gilles de Ia Tourette综合征，躁狂症，有机或NOS精神病，精神病，精神病，急性精神分裂症，慢性精神分裂症，精神分裂症精神分裂症 和相关疾病，糖尿病相关疾病，进行性多灶性脑白质病等。 本发明还涉及与单独或一起施用的其它药剂组合治疗5-HT2A 5-羟色胺受体介导的病症的方法。

    ACETAMIDE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO
    7.
    发明申请
    ACETAMIDE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO 审中-公开
    作为用于治疗相关疾病的5-HT2A丝氨酸受体的调节剂的乙酰胺衍生物

    公开(公告)号：WO2007136875A3

    公开(公告)日：2008-04-10

    申请号：PCT/US2007012230

    申请日：2007-05-17

    Applicant: ARENA PHARM INC ,  TEEGARDEN BRADLEY ,  FEICHTINGER KONRAD ,  STRAH-PLEYNET SONJA ,  ULMANN BRETT ,  XIONG YIFENG

    Inventor： TEEGARDEN BRADLEY ,  FEICHTINGER KONRAD ,  STRAH-PLEYNET SONJA ,  ULMANN BRETT ,  XIONG YIFENG

    IPC: C07D413/12 ,  A61K31/415 ,  C07D213/12 ,  C07D401/12 ,  C07D403/12 ,  C07D407/14

    CPC classification number: C07D231/16 ,  C07D231/12 ,  C07D401/12 ,  C07D405/12 ,  C07D417/12

    Abstract: The present invention pertains to certain compounds of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the 5-HT 2A serotonin receptor. Compounds and pharmaceutical compositions thereof are directed to methods useful in the treatment of platelet aggreagation, coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, atrial fibrillation, blood clot formation, asthma or symptoms thereof, agitation or a symptom thereof, behavioral disorders, drug induced psychosis, excitative psychosis, Gilles de la Tourette's syndrome, manic disorder, organic or NOS psychosis, psychotic disorder, psychosis, acute schizophrenia, chronic schizophrenia, NOS schizophrenia and related disorders, and sleep disorders, sleep disorders, diabetic-related disorders, progressive multifocal leukoencephalopathy and the like. The present invention also relates to the methods for the treatment of 5-HT 2A serotonin receptor associated disorders in combination with other pharmaceutical agents administered separately or together.

    Abstract translation: 本发明涉及某些式（Ia）的化合物及其药物组合物，其调节5-HT 2A 5-羟色胺受体的活性。 化合物及其药物组合物涉及可用于治疗血小板凝集，冠状动脉疾病，心肌梗塞，短暂性脑缺血发作，心绞痛，中风，心房颤动，血块形成，哮喘或其症状，躁动或其症状的方法， 精神病，精神病，急性精神分裂症，慢性精神分裂症，精神分裂症精神分裂症和相关疾病，睡眠障碍，睡眠障碍，糖尿病性精神病，精神病，精神病，精神病， 相关疾病，进行性多灶性脑白质病等。 本发明还涉及与单独或一起施用的其它药剂组合治疗5-HT 2A 5-羟色胺受体相关疾病的方法。

    ACETAMIDE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO
    10.
    发明申请
    ACETAMIDE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO 审中-公开
    作为用于治疗相关疾病的5-HT2A硒同位素受体的调节剂的乙酰胺衍生物

    公开(公告)号：WO2007136875A2

    公开(公告)日：2007-11-29

    申请号：PCT/US2007/012230

    申请日：2007-05-17

    Applicant: ARENA PHARMACEUTICALS, INC. ,  TEEGARDEN, Bradley ,  FEICHTINGER, Konrad ,  STRAH-PLEYNET, Sonja ,  ULMANN, Brett ,  XIONG, Yifeng

    Inventor： TEEGARDEN, Bradley ,  FEICHTINGER, Konrad ,  STRAH-PLEYNET, Sonja ,  ULMANN, Brett ,  XIONG, Yifeng

    CPC classification number: C07D231/16 ,  C07D231/12 ,  C07D401/12 ,  C07D405/12 ,  C07D417/12

    Abstract: The present invention pertains to certain compounds of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the 5-HT 2A serotonin receptor. Compounds and pharmaceutical compositions thereof are directed to methods useful in the treatment of platelet aggreagation, coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, atrial fibrillation, blood clot formation, asthma or symptoms thereof, agitation or a symptom thereof, behavioral disorders, drug induced psychosis, excitative psychosis, Gilles de la Tourette's syndrome, manic disorder, organic or NOS psychosis, psychotic disorder, psychosis, acute schizophrenia, chronic schizophrenia, NOS schizophrenia and related disorders, and sleep disorders, sleep disorders, diabetic-related disorders, progressive multifocal leukoencephalopathy and the like. The present invention also relates to the methods for the treatment of 5-HT 2A serotonin receptor associated disorders in combination with other pharmaceutical agents administered separately or together.

    Abstract translation: 本发明涉及调节5-HT 2A 2 5-羟色胺受体活性的某些式（Ia）化合物及其药物组合物。 化合物及其药物组合物涉及可用于治疗血小板凝集，冠状动脉疾病，心肌梗塞，短暂性脑缺血发作，心绞痛，中风，心房颤动，血块形成，哮喘或其症状，躁动或其症状的方法， 精神病，精神病，急性精神分裂症，慢性精神分裂症，精神分裂症精神分裂症和相关疾病，以及睡眠障碍，睡眠障碍，糖尿病性精神病，精神病性精神病，精神病性精神病，精神病性精神病， 相关疾病，进行性多灶性脑白质病等。 本发明还涉及与分开或一起施用的其它药剂组合治疗5-HT 2A 5-羟色胺受体相关疾病的方法。

Patent Agency Ranking